Evolus (EOLS) Research & Development (2017 - 2026)
Evolus (EOLS) posted Research & Development of $2.2 million for Q1 2026, down 35.65% on a QoQ basis from $3.5 million in Q4 2025, and up 1.27% year-over-year from $2.2 million in Q1 2025.
Evolus (EOLS) Research & Development (2017 - 2026) Analysis & Trends
Evolus' Research & Development history runs 10 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- Quarterly Research & Development rose 1.27% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.6 million (up 3.2% YoY) and the FY2025 annual result came in at $9.6 million, up 4.4% from the prior year.
- Research & Development was $2.2 million for Q1 2026 at Evolus, down from $3.5 million in the prior quarter.
- Across five years, Research & Development topped out at $3.5 million in Q4 2025 and bottomed at $468000.0 in Q1 2022.
- A 5-year average of $1.9 million and a median of $2.0 million in 2025 frame the typical range for Research & Development.
- Peak annual rise in Research & Development reached 357.14% in 2022, while the deepest fall reached 44.35% in 2022.
- Evolus' Research & Development stood at $1.3 million in 2022, then jumped by 76.56% to $2.4 million in 2023, then grew by 2.1% to $2.4 million in 2024, then surged by 43.25% to $3.5 million in 2025, then plunged by 35.65% to $2.2 million in 2026.
- Business Quant data shows EOLS's Research & Development at $2.2 million in Q1 2026, $3.5 million in Q4 2025, and $2.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 138.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | 2.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.24 Mn |
| Dec 31, 2025 | 3.48 Mn |
| Sep 30, 2025 | 2.05 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Dec 31, 2024 | 2.43 Mn |
| Sep 30, 2024 | 2.31 Mn |
| Jun 30, 2024 | 2.35 Mn |
| Mar 31, 2024 | 2.08 Mn |
| Dec 31, 2023 | 2.38 Mn |
| Sep 30, 2023 | 1.59 Mn |
| Jun 30, 2023 | 1.21 Mn |
| Mar 31, 2023 | 1.38 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | 1.38 Mn |
| Jun 30, 2022 | 1.55 Mn |
| Mar 31, 2022 | 468,000.00 |
| Dec 31, 2021 | 423,000.00 |
| Sep 30, 2021 | 301,000.00 |
| Jun 30, 2021 | 499,000.00 |